Bayer is investing over $300 million in CRISPR Therapeutics. As big money begins to get behind the technology, gene editing’s prospects are looking brighter than ever.
Great news for CRISPR
Pharmaceutical giant Bayer has announced a $300 million research investment for a joint venture with CRISPR Therapeutics. The small biotech is also receiving a $35 million equity investment. The venture has yet to be named, but their announced targets are thus far blindness, blood disorders and heart disease.
“Bayer and CRISPR Therapeutics are philosophically and financially aligned in our mission to develop game-changing or possibly curative treatments for serious human genetic diseases,” said Bayer CEO Marijn Dekkers
Read more at Fierce Biotech